Lacosamide Fresenius Kab (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons, stabilising hyper‑excitable membranes and reducing the repetitive firing that leads to seizure activity. This targeted action helps to lower the frequency of focal seizures.

The specific dose of lacosamide is determined by the prescribing clinician based on the patient’s age, weight, renal function, and response to therapy. Standard regimens often start with a loading dose followed by a maintenance infusion, but exact amounts must be individualized.

Lacosamide’s pregnancy category is listed as unknown, and limited human data are available. It should only be used during pregnancy or lactation when the potential benefit justifies any possible risk to the fetus or infant. Consultation with a specialist is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lacosamide differs from many traditional antiepileptics by selectively enhancing slow sodium‑channel inactivation, offering a distinct mechanism of action. Compared with drugs such as carbamazepine or levetiracetam, it may have a lower risk of enzyme‑inducing interactions but requires monitoring for cardiac conduction effects.

Lacosamide Fresenius Kab should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Do not freeze the solution, and keep the vial sealed until use to maintain sterility.

The product is administered intravenously by slow infusion, typically over 15 minutes for a loading dose followed by a maintenance infusion as directed by the prescriber. Administration should occur under medical supervision in a clinical setting.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation or atrioventricular block, which may lead to arrhythmias. Additionally, patients may experience suicidal thoughts or severe skin reactions like Stevens‑Johnson syndrome, requiring immediate medical attention.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid its use. Those with significant cardiac conduction disorders (e.g., existing AV block) or uncontrolled severe hepatic impairment should also be excluded unless a specialist determines it is safe.